Selection and characterization of DNA aptamer for metastatic prostate cancer recognition and tissue imaging

• DOI: 10.18632/oncotarget.9262
• Publication Date: 2016-05-10T10:26:21Z
• Authors: Minlan Duan; Yuqian Long; Cai Yang; Xiaoqiu Wu; Yang Sun; Jianglin Li; Xiaoxiao Hu; Wei Lin; Dongmei Han; Yifan Zhao; Jing Liu; Mao Ye; Weihong Tan
• Keywords: Aptamer; DU145

// Minlan Duan 1, * , Yuqian Long Cai Yang Xiaoqiu Wu 1 Sun Jianglin Li Xiaoxiao Hu Wei Lin Dongmei Han Yifan Zhao Jing Liu 2 Mao Ye Weihong Tan 3, 4 Molecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Biosensing Chemometrics, College of Biology, Chemistry Chemical Engineering, Collaborative Innovation Center Engineering Theranostics, Hunan University, Changsha, 410082, China School Life Sciences, Medical Genetics, Central South 410078, 3 Department Chemistry, Research at Bio/Nano Interface, University Health Cancer Center, Florida Genetics Institute McKnight Brain Institute, Florida, Gainesville, FL 32611, USA Physiology Functional Genomics, These authors contributed equally to this work Correspondence to: Tan, email: [e-mail] Ye, [e-mail] Keywords: prostate cancer, aptamer, SELEX, metastasis, binding affinity Received: January 28, 2016 Accepted: April 02, Published: May 10, ABSTRACT Prostate cancer (PCa) is the second leading cause death most prevalent in men. The absence curative options castration-resistant metastatic biomarkers able discriminate between indolent aggressive tumors contribute these statistics. In study, a DNA aptamer termed DML-7 was successfully selected against human PCa cell line DU145 by using cell-based systematic evolution ligands exponential enrichment (SELEX) method. found internalize into target cells temperature-dependent manner exhibit high with dissociation constants nanomolar range. Binding analysis further revealed that only binds PC-3 potential, but not LNCaP or 22Rv1 low nonmetastatic demonstrating has excellent selectivity recognition cells. Clinical tissue imaging confirmed results. Therefore, both specificity tissues afford potential development novel tool diagnosis targeted drug delivery cancer.